According to a newly released report from GlobalData Healthcare, The acute ischemic stroke (AIS) market is about to experience growth across the eight major markets (the 8MM: US, France, Germany, Italy, Spain, UK, Japan, and China) from 2017 to 2027.
The major barriers to the AIS market growth will be the availability of cheap and established anticoagulants such as warfarin, and the upcoming patent expiries of the branded non-vitamin K antagonist oral anticoagulants (NOACs) within 10 years. Despite this, market sales will increase across the 8MM due to the increasing incidence and prevalence of AIS as well as the anticipated launches of novel, presumably highly priced, neuroprotective drugs and stem cell therapies. China will experience the biggest increase in AIS patient population, according to GlobalData epidemiologists. As a result, China will experience the biggest market growth after the US, despite the lack of the new products launching in this market. GlobalData believes that the China AIS market holds a huge opportunity for drug companies pursuing development of drugs for post-stroke recovery.
AIS results from a complete blockage of a cerebral artery, leading to the death of brain cells and permanent damage. Current treatment of AIS centers around the restoration of blood flow to the brain by thrombolysis using Roche’s Activase (alteplase)—the only thrombolytic drug for AIS—or endovascular treatment to reverse ischemic stroke, or both in combination. After the acute event, antiplatelet, anticoagulant, statin, and antihypertensive drugs are used to prevent stroke recurrence.
EmstoPA is in a unique position to aid with post-stroke recovery, reversing the effects of tPA and encouraging further usage, which as a result, will vastly improve patient outcomes after a stroke.